HIV Disease Coverage Forecast and Market Analysis to 2027

CONTENTS

16 FORECAST: HIV (Published on 28 June 2019)
16 OVERVIEW
17 RECENT FORECAST UPDATES
18 MARKET DYNAMICS
21 FORECAST AND FUTURE TRENDS
27 MARKET DEFINITION AND METHODOLOGY
34 PRIMARY RESEARCH METHODOLOGY
37 BIBLIOGRAPHY
38 PRODUCT PROFILE: ATRIPLA
47 PRODUCT PROFILE: BIKTARVY
58 PRODUCT PROFILE: COMPLERA
68 PRODUCT PROFILE: DELSTRIGO
79 PRODUCT PROFILE: DESCOVY
89 PRODUCT PROFILE: DOVATO
98 PRODUCT PROFILE: GENVOYA
108 PRODUCT PROFILE: ISENTRESS
117 PRODUCT PROFILE: JULUCA
126 PRODUCT PROFILE: ODEFSEY
136 PRODUCT PROFILE: PREZISTA FRANCHISE
152 PRODUCT PROFILE: REYATAZ FRANCHISE
165 PRODUCT PROFILE: STRIBILD
176 PRODUCT PROFILE: SYMTUZA
187 PRODUCT PROFILE: TIVICAY
198 PRODUCT PROFILE: TRIUMEQ
209 PRODUCT PROFILE: TROGARZO
217 PRODUCT PROFILE: TRUVADA
227 PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
236 PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR
246 PRODUCT PROFILE (LATE STAGE): LERONLIMAB

255 TREATMENT: HIV (Published on 13 April 2018)
255 OVERVIEW
256 PRIMARY RESEARCH METHODOLOGY
259 DISEASE DEFINITION AND DIAGNOSIS
271 PATIENT SEGMENTATION
276 CURRENT TREATMENT OPTIONS
282 TREATMENT GUIDELINES
288 PRESCRIBING TRENDS
303 UNMET NEEDS IN HIV
307 IMPACT OF GENERICS

312 EPIDEMIOLOGY: HIV (Published on 25 January 2019)
312 OVERVIEW
314 DISEASE BACKGROUND
317 METHODOLOGY
333 FORECAST
349 BIBLIOGRAPHY
354 APPENDIX: ADDITIONAL SOURCES

355 MARKETED DRUGS: HIV (Published on 28 June 2019)
355 OVERVIEW
356 PRODUCT OVERVIEW
359 PRODUCT PROFILE: ATRIPLA
368 PRODUCT PROFILE: BIKTARVY
379 PRODUCT PROFILE: COMPLERA
389 PRODUCT PROFILE: DELSTRIGO
400 PRODUCT PROFILE: DESCOVY
410 PRODUCT PROFILE: DOVATO
419 PRODUCT PROFILE: GENVOYA
429 PRODUCT PROFILE: ISENTRESS
438 PRODUCT PROFILE: JULUCA
447 PRODUCT PROFILE: ODEFSEY
457 PRODUCT PROFILE: PREZISTA FRANCHISE
473 PRODUCT PROFILE: REYATAZ FRANCHISE
486 PRODUCT PROFILE: STRIBILD
497 PRODUCT PROFILE: SYMTUZA
508 PRODUCT PROFILE: TIVICAY
519 PRODUCT PROFILE: TRIUMEQ
530 PRODUCT PROFILE: TROGARZO
538 PRODUCT PROFILE: TRUVADA

548 PIPELINE: HIV (Published on 28 June 2019)
548 OVERVIEW
549 CLINICAL PIPELINE OVERVIEW
550 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
551 PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
560 PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR
570 PRODUCT PROFILE (LATE STAGE): LERONLIMAB

LIST OF FIGURES
20 Figure 1: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for HIV
22 Figure 2: HIV total market value across the US and five major EU markets, by country, 2018−27
23 Figure 3: HIV total market value across the US and five major EU markets, by class, 2018−27
24 Figure 4: HIV sales in the US, 2018–27
25 Figure 5: HIV sales in the five major EU markets, by country, 2018–27
26 Figure 6: Sales of Biktarvy compared to INSTI-based STRs and injectables, by product, 2018–27
30 Figure 7: Datamonitor Healthcare’s HIV forecast methodology
32 Figure 8: Price sources and calculations, by country
42 Figure 9: Datamonitor Healthcare’s drug assessment summary of Atripla for HIV
43 Figure 10: Datamonitor Healthcare’s drug assessment summary of Atripla for HIV
45 Figure 11: Atripla sales for HIV across the US and five major EU markets, by country, 2018–27
53 Figure 12: Datamonitor Healthcare’s drug assessment summary of Biktarvy for HIV
54 Figure 13: Datamonitor Healthcare’s drug assessment summary of Biktarvy for HIV
57 Figure 14: Biktarvy sales for HIV across the US and five major EU markets, by country, 2018–27
63 Figure 15: Datamonitor Healthcare’s drug assessment summary of Complera for HIV
64 Figure 16: Datamonitor Healthcare’s drug assessment summary of Complera for HIV
66 Figure 17: Complera sales for HIV across the US and five major EU markets, by country, 2018–27
73 Figure 18: Datamonitor Healthcare’s drug assessment summary of Delstrigo for HIV
74 Figure 19: Datamonitor Healthcare’s drug assessment summary of Delstrigo for HIV
77 Figure 20: Delstrigo sales for HIV across the US and five major EU markets, by country, 2018–27
85 Figure 21: Datamonitor Healthcare’s drug assessment summary of Descovy for HIV
86 Figure 22: Datamonitor Healthcare’s drug assessment summary of Descovy for HIV
88 Figure 23: Descovy sales for HIV across the US and five major EU markets, by country, 2018–27
94 Figure 24: Datamonitor Healthcare’s drug assessment summary of Dovato for HIV
95 Figure 25: Datamonitor Healthcare’s drug assessment summary of Dovato for HIV
97 Figure 26: Dovato sales for HIV across the US and five major EU markets, by country, 2018–27
104 Figure 27: Datamonitor Healthcare’s drug assessment summary of Genvoya for HIV
105 Figure 28: Datamonitor Healthcare’s drug assessment summary of Genvoya for HIV
107 Figure 29: Genvoya sales for HIV across the US and five major EU markets, by country, 2018–27
113 Figure 30: Datamonitor Healthcare’s drug assessment summary of Isentress for HIV
114 Figure 31: Datamonitor Healthcare’s drug assessment summary of Isentress for HIV
116 Figure 32: Isentress sales for HIV across the US and five major EU markets, by country, 2018–27
122 Figure 33: Datamonitor Healthcare’s drug assessment summary of Juluca for HIV
123 Figure 34: Datamonitor Healthcare’s drug assessment summary of Juluca for HIV
125 Figure 35: Juluca sales for HIV across the US and five major EU markets, by country, 2018–27
131 Figure 36: Datamonitor Healthcare’s drug assessment summary of Odefsey for HIV
132 Figure 37: Datamonitor Healthcare’s drug assessment summary of Odefsey for HIV
134 Figure 38: Odefsey sales for HIV across the US and five major EU markets, by country, 2018–27
145 Figure 39: Datamonitor Healthcare’s drug assessment summary of Prezista franchise for HIV
146 Figure 40: Datamonitor Healthcare’s drug assessment summary of Prezista franchise for HIV
149 Figure 41: Prezista sales for HIV across the US and five major EU markets, by country, 2018–27
150 Figure 42: Prezcobix sales for HIV across the US and five major EU markets, by country, 2018–27
159 Figure 43: Datamonitor Healthcare’s drug assessment summary of Reyataz franchise for HIV
160 Figure 44: Datamonitor Healthcare’s drug assessment summary of Reyataz franchise for HIV
162 Figure 45: Reyataz sales for HIV across the US and five major EU markets, by country, 2018–27
163 Figure 46: Evotaz sales for HIV across the US and five major EU markets, by country, 2018–27
171 Figure 47: Datamonitor Healthcare’s drug assessment summary of Stribild for HIV
172 Figure 48: Datamonitor Healthcare’s drug assessment summary of Stribild for HIV
174 Figure 49: Stribild sales for HIV across the US and five major EU markets, by country, 2018–27
181 Figure 50: Datamonitor Healthcare’s drug assessment summary of Symtuza for HIV
182 Figure 51: Datamonitor Healthcare’s drug assessment summary of Symtuza for HIV
185 Figure 52: Symtuza sales for HIV across the US and five major EU markets, by country, 2018–27
193 Figure 53: Datamonitor Healthcare’s drug assessment summary of Tivicay for HIV
194 Figure 54: Datamonitor Healthcare’s drug assessment summary of Tivicay for HIV
196 Figure 55: Tivicay sales for HIV across the US and five major EU markets, by country, 2018–27
203 Figure 56: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
204 Figure 57: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
207 Figure 58: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
213 Figure 59: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
214 Figure 60: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
216 Figure 61: Trogarzo sales for HIV across the US and five major EU markets, by country, 2018–27
222 Figure 62: Datamonitor Healthcare’s drug assessment summary of Truvada for HIV
223 Figure 63: Datamonitor Healthcare’s drug assessment summary of Truvada for HIV
225 Figure 64: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
232 Figure 65: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
233 Figure 66: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
235 Figure 67: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
241 Figure 68: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
242 Figure 69: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
244 Figure 70: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2018–27
251 Figure 71: Datamonitor Healthcare’s drug assessment summary of leronlimab for HIV
252 Figure 72: Datamonitor Healthcare’s drug assessment summary of leronlimab for HIV
254 Figure 73: Leronlimab sales for HIV in the US, 2018–27
265 Figure 74: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
266 Figure 75: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
275 Figure 76: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
283 Figure 77: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
288 Figure 78: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
290 Figure 79: Top five brands used for the treatment of first-line HIV patients, by country
291 Figure 80: Top five regimens used for the treatment of first-line HIV patients, by country
294 Figure 81: Top five regimens used for the treatment of second-line HIV patients, by country
295 Figure 82: Top five brands used for the treatment of second-line HIV patients, by country
297 Figure 83: Top five regimens used for the treatment of third-line HIV patients, by country
298 Figure 84: Top five brands used for the treatment of third-line HIV patients, by country
299 Figure 85: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
300 Figure 86: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
303 Figure 87: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
308 Figure 88: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
309 Figure 89: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
310 Figure 90: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
363 Figure 91: Datamonitor Healthcare’s drug assessment summary of Atripla for HIV
364 Figure 92: Datamonitor Healthcare’s drug assessment summary of Atripla for HIV
366 Figure 93: Atripla sales for HIV across the US and five major EU markets, by country, 2018–27
374 Figure 94: Datamonitor Healthcare’s drug assessment summary of Biktarvy for HIV
375 Figure 95: Datamonitor Healthcare’s drug assessment summary of Biktarvy for HIV
378 Figure 96: Biktarvy sales for HIV across the US and five major EU markets, by country, 2018–27
384 Figure 97: Datamonitor Healthcare’s drug assessment summary of Complera for HIV
385 Figure 98: Datamonitor Healthcare’s drug assessment summary of Complera for HIV
387 Figure 99: Complera sales for HIV across the US and five major EU markets, by country, 2018–27
394 Figure 100: Datamonitor Healthcare’s drug assessment summary of Delstrigo for HIV
395 Figure 101: Datamonitor Healthcare’s drug assessment summary of Delstrigo for HIV
398 Figure 102: Delstrigo sales for HIV across the US and five major EU markets, by country, 2018–27
406 Figure 103: Datamonitor Healthcare’s drug assessment summary of Descovy for HIV
407 Figure 104: Datamonitor Healthcare’s drug assessment summary of Descovy for HIV
409 Figure 105: Descovy sales for HIV across the US and five major EU markets, by country, 2018–27
415 Figure 106: Datamonitor Healthcare’s drug assessment summary of Dovato for HIV
416 Figure 107: Datamonitor Healthcare’s drug assessment summary of Dovato for HIV
418 Figure 108: Dovato sales for HIV across the US and five major EU markets, by country, 2018–27
425 Figure 109: Datamonitor Healthcare’s drug assessment summary of Genvoya for HIV
426 Figure 110: Datamonitor Healthcare’s drug assessment summary of Genvoya for HIV
428 Figure 111: Genvoya sales for HIV across the US and five major EU markets, by country, 2018–27
434 Figure 112: Datamonitor Healthcare’s drug assessment summary of Isentress for HIV
435 Figure 113: Datamonitor Healthcare’s drug assessment summary of Isentress for HIV
437 Figure 114: Isentress sales for HIV across the US and five major EU markets, by country, 2018–27
443 Figure 115: Datamonitor Healthcare’s drug assessment summary of Juluca for HIV
444 Figure 116: Datamonitor Healthcare’s drug assessment summary of Juluca for HIV
446 Figure 117: Juluca sales for HIV across the US and five major EU markets, by country, 2018–27
452 Figure 118: Datamonitor Healthcare’s drug assessment summary of Odefsey for HIV
453 Figure 119: Datamonitor Healthcare’s drug assessment summary of Odefsey for HIV
455 Figure 120: Odefsey sales for HIV across the US and five major EU markets, by country, 2018–27
466 Figure 121: Datamonitor Healthcare’s drug assessment summary of Prezista franchise for HIV
467 Figure 122: Datamonitor Healthcare’s drug assessment summary of Prezista franchise for HIV
470 Figure 123: Prezista sales for HIV across the US and five major EU markets, by country, 2018–27
471 Figure 124: Prezcobix sales for HIV across the US and five major EU markets, by country, 2018–27
480 Figure 125: Datamonitor Healthcare’s drug assessment summary of Reyataz franchise for HIV
481 Figure 126: Datamonitor Healthcare’s drug assessment summary of Reyataz franchise for HIV
483 Figure 127: Reyataz sales for HIV across the US and five major EU markets, by country, 2018–27
484 Figure 128: Evotaz sales for HIV across the US and five major EU markets, by country, 2018–27
492 Figure 129: Datamonitor Healthcare’s drug assessment summary of Stribild for HIV
493 Figure 130: Datamonitor Healthcare’s drug assessment summary of Stribild for HIV
495 Figure 131: Stribild sales for HIV across the US and five major EU markets, by country, 2018–27
502 Figure 132: Datamonitor Healthcare’s drug assessment summary of Symtuza for HIV
503 Figure 133: Datamonitor Healthcare’s drug assessment summary of Symtuza for HIV
506 Figure 134: Symtuza sales for HIV across the US and five major EU markets, by country, 2018–27
514 Figure 135: Datamonitor Healthcare’s drug assessment summary of Tivicay for HIV
515 Figure 136: Datamonitor Healthcare’s drug assessment summary of Tivicay for HIV
517 Figure 137: Tivicay sales for HIV across the US and five major EU markets, by country, 2018–27
524 Figure 138: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
525 Figure 139: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
528 Figure 140: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
534 Figure 141: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
535 Figure 142: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV
537 Figure 143: Trogarzo sales for HIV across the US and five major EU markets, by country, 2018–27
543 Figure 144: Datamonitor Healthcare’s drug assessment summary of Truvada for HIV
544 Figure 145: Datamonitor Healthcare’s drug assessment summary of Truvada for HIV
546 Figure 146: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
556 Figure 147: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
557 Figure 148: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
559 Figure 149: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2018–27
565 Figure 150: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
566 Figure 151: Datamonitor Healthcare’s drug assessment summary of fostemsavir for HIV
568 Figure 152: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2018–27
575 Figure 153: Datamonitor Healthcare’s drug assessment summary of leronlimab for HIV
576 Figure 154: Datamonitor Healthcare’s drug assessment summary of leronlimab for HIV
578 Figure 155: Leronlimab sales for HIV in the US, 2018–27

LIST OF TABLES
17 Table 1: Recent events incorporated into the HIV forecast
19 Table 2: HIV – current and future market dynamics analysis
21 Table 3: HIV – current and future forecast trends
33 Table 4: Exchange rates used for calculating prices
35 Table 5: Infectious disease specialists surveyed for the HIV primary research study, 2017
38 Table 6: Atripla drug profile
39 Table 7: Approval history of Atripla for HIV in the US and five major EU markets
40 Table 8: Late-phase trials of Atripla for HIV
41 Table 9: Atripla for HIV – SWOT analysis
48 Table 10: Biktarvy drug profile
48 Table 11: Approval history of Biktarvy for HIV in the US, Japan, and five major EU markets
50 Table 12: Late-phase trials of Biktarvy for HIV
52 Table 13: Biktarvy for HIV – SWOT analysis
59 Table 14: Complera drug profile
60 Table 15: Approval history of Complera for HIV in the US, Japan, and five major EU markets
61 Table 16: Late-phase trials of Complera for HIV
62 Table 17: Complera for HIV – SWOT analysis
69 Table 18: Delstrigo drug profile
69 Table 19: Approval history of Delstrigo for HIV in the US and five major EU markets
71 Table 20: Late-phase trials of Delstrigo for HIV
72 Table 21: Delstrigo for HIV – SWOT analysis
80 Table 22: Descovy drug profile
80 Table 23: Approval history of Descovy for HIV in the US, Japan, and five major EU markets
82 Table 24: Late-phase trials of Descovy for HIV
84 Table 25: Descovy for HIV – SWOT analysis
90 Table 26: Dovato drug profile
91 Table 27: Approval history of Dovato for HIV in the US
92 Table 28: Late-phase trials of Dovato for HIV
93 Table 29: Dovato for HIV – SWOT analysis
99 Table 30: Genvoya drug profile
99 Table 31: Approval history of Genvoya for HIV in the US, Japan, and five major EU markets
101 Table 32: Late-phase trials of Genvoya for HIV
103 Table 33: Genvoya for HIV – SWOT analysis
108 Table 34: Isentress drug profile
109 Table 35: Approval history of Isentress for HIV in the US, Japan, and five major EU markets
111 Table 36: Late-phase trials of Isentress for HIV
112 Table 37: Isentress for HIV – SWOT analysis
118 Table 38: Juluca drug profile
119 Table 39: Approval history of Juluca for HIV in the US, Japan, and five major EU markets
120 Table 40: Late-phase trials of Juluca for HIV
121 Table 41: Juluca for HIV – SWOT analysis
127 Table 42: Odefsey drug profile
127 Table 43: Approval history of Odefsey for HIV in the US and five major EU markets
129 Table 44: Late-phase trials of Odefsey for HIV
130 Table 45: Odefsey for HIV – SWOT analysis
136 Table 46: Prezista drug profile
137 Table 47: Prezcobix drug profile
138 Table 48: Approval history of Prezista for HIV in the US, Japan, and five major EU markets
140 Table 49: Late-phase trials of Prezista for HIV
142 Table 50: Approval history of Prezcobix for HIV in the US, Japan, and five major EU markets
143 Table 51: Late-phase trials of Prezcobix for HIV
144 Table 52: Prezista franchise for HIV – SWOT analysis
153 Table 53: Reyataz drug profile
153 Table 54: Evotaz drug profile
154 Table 55: Approval history of Reyataz for HIV in the US, Japan, and five major EU markets
155 Table 56: Late-phase trials of Reyataz for HIV
156 Table 57: Approval history of Evotaz for HIV in the US and five major EU markets
157 Table 58: Late-phase trials of Evotaz for HIV
158 Table 59: Reyataz franchise for HIV – SWOT analysis
166 Table 60: Stribild drug profile
167 Table 61: Approval history of Stribild for HIV in the US, Japan, and five major EU markets
168 Table 62: Late-phase trials of Stribild for HIV
170 Table 63: Stribild for HIV – SWOT analysis
177 Table 64: Symtuza drug profile
177 Table 65: Approval history of Symtuza for HIV in the US and five major EU markets
179 Table 66: Late-phase trials of Symtuza for HIV
180 Table 67: Symtuza for HIV – SWOT analysis
188 Table 68: Tivicay drug profile
189 Table 69: Approval history of Tivicay for HIV in the US, Japan, and five major EU markets
190 Table 70: Late-phase trials of Tivicay for HIV
192 Table 71: Tivicay for HIV – SWOT analysis
199 Table 72: Triumeq drug profile
199 Table 73: Approval history of Triumeq for HIV in the US, Japan, and five major EU markets
201 Table 74: Late-phase trials of Triumeq for HIV
202 Table 75: Triumeq for HIV – SWOT analysis
209 Table 76: Trogarzo drug profile
210 Table 77: Approval history of Trogarzo for HIV in the US
211 Table 78: Late-phase trials of Trogarzo for HIV
212 Table 79: Trogarzo for HIV – SWOT analysis
218 Table 80: Truvada drug profile
219 Table 81: Approval history of Truvada for HIV in the US, Japan, and five major EU markets
220 Table 82: Late-phase trials of Truvada for HIV
221 Table 83: Truvada for HIV – SWOT analysis
228 Table 84: Cabotegravir/rilpivirine drug profile
230 Table 85: Late-phase trials of cabotegravir/rilpivirine for HIV
231 Table 86: Cabotegravir/rilpivirine for HIV – SWOT analysis
237 Table 87: Fostemsavir drug profile
239 Table 88: Late-phase trials of fostemsavir for HIV
240 Table 89: Fostemsavir for HIV – SWOT analysis
247 Table 90: Leronlimab drug profile
249 Table 91: Late-phase trials of leronlimab for HIV
250 Table 92: Leronlimab for HIV – SWOT analysis
256 Table 93: Infectious disease specialists surveyed for the HIV primary research study, 2017
258 Table 94: Therapies discussed in the HIV key opinion leader primary research study, 2017
259 Table 95: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
260 Table 96: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
261 Table 97: Per-act HIV transmission risk, by transmission route
271 Table 98: CDC classification system for HIV-infected adults and adolescents
272 Table 99: Symptomatic conditions included in CDC HIV classification system clinical categories
273 Table 100: WHO clinical staging of HIV/AIDS for adults and adolescents
277 Table 101: Treatments available for HIV across the US and five major EU markets
285 Table 102: Summary of “recommended” treatment options in HHS and EACS treatment guidelines
315 Table 103: HIV prevalence, infections, and AIDS-attributable deaths in 2017, by region
318 Table 104: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
326 Table 105: Data sources used to describe the diagnosed prevalent HIV population, by country
328 Table 106: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
330 Table 107: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
334 Table 108: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
336 Table 109: Incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2018
338 Table 110: Number and proportion of incident HIV cases, by transmission route, and country, 2018
341 Table 111: Total prevalent cases of HIV in the US, Japan, and five major EU markets, by country, 2018–28
345 Table 112: Diagnosed and undiagnosed prevalent HIV cases, by country, 2018
346 Table 113: Co-morbid bone and renal impairments in adult diagnosed prevalent HIV cases, by country, 2018
357 Table 114: Profiled key marketed drugs for HIV
359 Table 115: Atripla drug profile
360 Table 116: Approval history of Atripla for HIV in the US and five major EU markets
361 Table 117: Late-phase trials of Atripla for HIV
362 Table 118: Atripla for HIV – SWOT analysis
369 Table 119: Biktarvy drug profile
369 Table 120: Approval history of Biktarvy for HIV in the US, Japan, and five major EU markets
371 Table 121: Late-phase trials of Biktarvy for HIV
373 Table 122: Biktarvy for HIV – SWOT analysis
380 Table 123: Complera drug profile
381 Table 124: Approval history of Complera for HIV in the US, Japan, and five major EU markets
382 Table 125: Late-phase trials of Complera for HIV
383 Table 126: Complera for HIV – SWOT analysis
390 Table 127: Delstrigo drug profile
390 Table 128: Approval history of Delstrigo for HIV in the US and five major EU markets
392 Table 129: Late-phase trials of Delstrigo for HIV
393 Table 130: Delstrigo for HIV – SWOT analysis
401 Table 131: Descovy drug profile
401 Table 132: Approval history of Descovy for HIV in the US, Japan, and five major EU markets
403 Table 133: Late-phase trials of Descovy for HIV
405 Table 134: Descovy for HIV – SWOT analysis
411 Table 135: Dovato drug profile
412 Table 136: Approval history of Dovato for HIV in the US
413 Table 137: Late-phase trials of Dovato for HIV
414 Table 138: Dovato for HIV – SWOT analysis
420 Table 139: Genvoya drug profile
420 Table 140: Approval history of Genvoya for HIV in the US, Japan, and five major EU markets
422 Table 141: Late-phase trials of Genvoya for HIV
424 Table 142: Genvoya for HIV – SWOT analysis
429 Table 143: Isentress drug profile
430 Table 144: Approval history of Isentress for HIV in the US, Japan, and five major EU markets
432 Table 145: Late-phase trials of Isentress for HIV
433 Table 146: Isentress for HIV – SWOT analysis
439 Table 147: Juluca drug profile
440 Table 148: Approval history of Juluca for HIV in the US, Japan, and five major EU markets
441 Table 149: Late-phase trials of Juluca for HIV
442 Table 150: Juluca for HIV – SWOT analysis
448 Table 151: Odefsey drug profile
448 Table 152: Approval history of Odefsey for HIV in the US and five major EU markets
450 Table 153: Late-phase trials of Odefsey for HIV
451 Table 154: Odefsey for HIV – SWOT analysis
457 Table 155: Prezista drug profile
458 Table 156: Prezcobix drug profile
459 Table 157: Approval history of Prezista for HIV in the US, Japan, and five major EU markets
461 Table 158: Late-phase trials of Prezista for HIV
463 Table 159: Approval history of Prezcobix for HIV in the US, Japan, and five major EU markets
464 Table 160: Late-phase trials of Prezcobix for HIV
465 Table 161: Prezista franchise for HIV – SWOT analysis
474 Table 162: Reyataz drug profile
474 Table 163: Evotaz drug profile
475 Table 164: Approval history of Reyataz for HIV in the US, Japan, and five major EU markets
476 Table 165: Late-phase trials of Reyataz for HIV
477 Table 166: Approval history of Evotaz for HIV in the US and five major EU markets
478 Table 167: Late-phase trials of Evotaz for HIV
479 Table 168: Reyataz franchise for HIV – SWOT analysis
487 Table 169: Stribild drug profile
488 Table 170: Approval history of Stribild for HIV in the US, Japan, and five major EU markets
489 Table 171: Late-phase trials of Stribild for HIV
491 Table 172: Stribild for HIV – SWOT analysis
498 Table 173: Symtuza drug profile
498 Table 174: Approval history of Symtuza for HIV in the US and five major EU markets
500 Table 175: Late-phase trials of Symtuza for HIV
501 Table 176: Symtuza for HIV – SWOT analysis
509 Table 177: Tivicay drug profile
510 Table 178: Approval history of Tivicay for HIV in the US, Japan, and five major EU markets
511 Table 179: Late-phase trials of Tivicay for HIV
513 Table 180: Tivicay for HIV – SWOT analysis
520 Table 181: Triumeq drug profile
520 Table 182: Approval history of Triumeq for HIV in the US, Japan, and five major EU markets
522 Table 183: Late-phase trials of Triumeq for HIV
523 Table 184: Triumeq for HIV – SWOT analysis
530 Table 185: Trogarzo drug profile
531 Table 186: Approval history of Trogarzo for HIV in the US
532 Table 187: Late-phase trials of Trogarzo for HIV
533 Table 188: Trogarzo for HIV – SWOT analysis
539 Table 189: Truvada drug profile
540 Table 190: Approval history of Truvada for HIV in the US, Japan, and five major EU markets
541 Table 191: Late-phase trials of Truvada for HIV
542 Table 192: Truvada for HIV – SWOT analysis
549 Table 193: Profiled pipeline products in development for HIV
552 Table 194: Cabotegravir/rilpivirine drug profile
554 Table 195: Late-phase trials of cabotegravir/rilpivirine for HIV
555 Table 196: Cabotegravir/rilpivirine for HIV – SWOT analysis
561 Table 197: Fostemsavir drug profile
563 Table 198: Late-phase trials of fostemsavir for HIV
564 Table 199: Fostemsavir for HIV – SWOT analysis
571 Table 200: Leronlimab drug profile
573 Table 201: Late-phase trials of leronlimab for HIV
574 Table 202: Leronlimab for HIV – SWOT analysis